Indication

In combination with nab-paclitaxel for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) whose tumours have PD-L1 expression ≥  1% and who have not received prior chemotherapy for metastatic disease.

Medicine details

Medicine name:
atezolizumab (Tecentriq)
SMC ID:
SMC2267
Pharmaceutical company
Roche
BNF chapter
Malignant disease and immunosuppression
Submission type
Full
Publication due date:
Q4 2020
SMC meeting date:
Q4 2020
Patient group submission deadline:
06 July 2020